The adoption of biosimilars is generally seen as a cost-saving measure for pharmacy benefits managers like CVS Caremark. By excluding Humira from their formularies, CVS may reduce expenses and improve margins, which could be seen positively by investors in the short term. However, the actual impact on the stock will depend on the market's perception of the potential savings and the company's ability to manage the transition smoothly.